25523-97-1

Basic information

• Product Name: DEXCHLORPHENIRAMINE
• Synonyms: chlo-amine;2-Pyridinepropanamine, γ-(4-chlorophenyl)-N,N-dimethyl-, (γS)-;Pyridine, 2-[p-chloro-α-[2-(dimethylamino)ethyl]benzyl]-, (S)-(+)- (8CI);S-(+)-Chlorpheniramine;S-Chlorpheniramine;Dexchlorpheniramine (base and/or unspecified salts);(+)-2-[(S)-p-Chloro-α-[2-(dimethylamino)ethyl]benzyl]pyridine;(S)-γ-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropan-1-amine
• CAS NO: 25523-97-1
• Molecular Formula: C₁₆H₁₉ClN₂
• Molecular Weight: 274.79
• EINECS: 247-073-7
• Mol File: 25523-97-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 379°Cat760mmHg
• Flash Point: 183°C
• Appearance: /
• Density: 1.107g/cm³
• Refractive Index: 1.565
• PKA: 9.33±0.28(Predicted)
• CAS DataBase Reference: DEXCHLORPHENIRAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: DEXCHLORPHENIRAMINE(25523-97-1)
• EPA Substance Registry System: DEXCHLORPHENIRAMINE(25523-97-1)

Safety Data

• Hazardous Substances Data: 25523-97-1(Hazardous Substances Data)

Usage

Description

DEXCHLORPHENIRAMINE is an antihistamine medication that is known for its potent antihistaminic properties. It is structurally similar to chlorpheniramine, with the addition of a dextrotropic group, which enhances its activity. DEXCHLORPHENIRAMINE is characterized by its ability to effectively alleviate allergy symptoms, rhinitis, and dermatitis due to its strong antihistaminic action.

Uses

Used in Pharmaceutical Industry:
DEXCHLORPHENIRAMINE is used as an antihistaminic agent for treating various allergy symptoms. Its application reason is based on its ability to block the action of histamine, a substance released during an allergic reaction, which causes symptoms such as itching, redness, and swelling.
DEXCHLORPHENIRAMINE is used as a medication for rhinitis, particularly for its effectiveness in reducing nasal congestion and other related symptoms. The application reason is due to its potent antihistaminic activity, which helps alleviate the inflammation and discomfort associated with rhinitis.
DEXCHLORPHENIRAMINE is also used as a treatment for dermatitis, a condition characterized by skin inflammation and itching. The application reason is its ability to counteract the effects of histamine on the skin, providing relief from itching and redness.

Therapeutic Function

Antihistaminic

InChI:InChI=1/C16H19ClN2/c1-19(2)11-9-16(14-4-3-10-18-12-14)13-5-7-15(17)8-6-13/h3-8,10,12,16H,9,11H2,1-2H3/t16-/m0/s1

Upstream product

• 7340-23-0 ethyl 3-(pyridin-2-yl)acrylate 
• 1679-18-1 4-Chlorophenylboronic acid 
• 132-22-9 Chlorpheniramine 

Relevant articles and documents

-

-

Asymmetric synthesis method of dexchlorpheniramine and dexbrompheniramine

The invention belongs to the field of chemical synthesis and discloses a asymmetric synthesis method of dexhalopheniramine, wherein the method comprises the following steps: in the presence of alkali,carrying out a reaction on 3-(2-pyridyl) ethyl acrylate and 4-chlorophenylboronic acid or 4-bromophenylboronic acid under the action of a chiral rhodium catalyst to obtain an asymmetric addition product, wherein the single-step yield can reach up to 96%, and the ee value reaches 96%; hydrolyzing the asymmetric addition product to obtain corresponding acid, and condensing the acid with dimethylamine hydrochloride to obtain corresponding amide; and reducing the amide to obtain a target end product. The raw materials of the route are cheap and easy to obtain, the route is short, the enantioselectivity of the product is high, the total yield is about 75%, and the method has high industrial production value.

Synthesis of dendrimer-type chiral stationary phases based on the selector of (1S,2R)-(+)-2-amino-1,2-diphenylethanol derivate and their enantioseparation evaluation by HPLC

In our recent work, a series of dendritic chiral stationary phases (CSPs) were synthesized, in which the chiral selector was L-2-(p-toluenesulfonamido)-3- phenylpropionyl chloride (selector I), and the CSP derived from three-generation dendrimer showed the best separation ability. To further investigate the influence of the structures of dendrimer and chiral selector on enantioseparation ability, in this work, another series CSPs (CSPs 1-4) were prepared by immobilizing (1S,2R)-1,2-diphenyl-2-(3-phenylureido)ethyl 4-isocyanatophenylcarbamate (selector II) on one- to four-generation dendrimers that were prepared in previous work. CSPs 1 and 4 demonstrated the equivalent enantioseparation ability. CSPs 2 and 3 showed the best and poorest enantioseparation ability respectively. Basically, these two series of CSPs exhibited the equivalent enantioseparation ability although the chiral selectors were different. Considering the enantioseparation ability of the CSP derived from aminated silica gel and selector II is much better than that of the one derived from aminated silica gel and selector I, it is believed that the dendrimer conformation essentially impacts enantioseparation.